Q-omics provides the consensus-scored LINC01619 profile across patient tissues and cancer cell-line models. LINC01619 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC01619 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, LINC01619 RNA expression shows 15,920 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight HNSC, and KIRP as cancer lineages where LINC01619 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01619 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01619 survival associations across molecular data types. LINC01619 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01619 RNA expression–survival associations across cancer types. High LINC01619 expression shows unfavorable associations in KICH, but favorable associations in HNSC, OV, CESC, STAD and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC01619 RNA expression.
This table summarizes LINC01619 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01619. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01619 shows lower tumor expression in BRCA, UCEC and KICH and higher tumor expression in HNSC, KIRC and STAD. The HNSC box plot shows higher LINC01619 RNA expression in tumor versus normal tissue (log2 FC = +0.332, t-test p < 0.001).
This table shows molecular features associated with LINC01619 in patient tissues and cancer cell lines. In patient samples, LINC01619 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC01619 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT.
